SLC7A11 and obstructive sleep apnea syndrome: Several compounds have been identified that exploit this vulnerability in OSA cells: Sulforaphane promotes the interaction between p62 and xCT, leading to the autolysosomal degradation of xCT [21]; Baicalin and Shikonin induce NRF2 ubiquitin degradation, which suppresses downstream targets expression, including xCT [22,23]; Sulfasalazine (SAS), an FDA- and EMA-approved drug, inhibits xCT antiporter function [24].